Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nosebleed Clear all
Withdrawn Phase 1 Interventional

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

NCT07255846
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
TER-1754, Placebo
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 4 Interventional Results available

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

NCT02930941
View directory record Official record
Conditions
Epistaxis
Interventions
Tranexamic Acid, 0.9% Sodium Chloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial

NCT04167085
View directory record Official record
Conditions
Epistaxis
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01408030
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01397695
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

, "Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"

NCT02517294
View directory record Official record
Conditions
Epistaxis
Interventions
Parker flex-tip nasotracheal tube, Standard nasotracheal tube
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 11 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer

NCT02338102
View directory record Official record
Conditions
Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions
Saline mixture
Other
Lead sponsor
Lisa Shnayder
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting Phase 3 Interventional

RADA16 for Adult Tonsillectomy

NCT07060495
View directory record Official record
Conditions
Postoperative Pain
Interventions
RADA16 hydrogel
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Livingston, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT04139018
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Timolol Gel, Placebo Gel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis

NCT00863356
View directory record Official record
Conditions
Epistaxis
Interventions
2009-I-Epistaxis-1
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for the Treatment of Bleeding in HHT

NCT03910244
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pomalidomide Oral Product, Placebo oral capsule
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

NCT06259292
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
Interventions
Not listed
Lead sponsor
Cure HHT
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01402531
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Submucosal Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Withdrawn Not applicable Interventional

Microporous Polysaccharide Hemospheres Epistaxis

NCT02466464
View directory record Official record
Conditions
Epistaxis
Interventions
Microporous Polysaccharide Hemospheres, Nasal Tampon
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

NCT02285634
View directory record Official record
Conditions
Epistaxis, Blood Pressure
Interventions
Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 22, 2026, 9:57 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Intranasal TXA for Anterior Epistaxis in the Emergency Department

NCT04054687
View directory record Official record
Conditions
Epistaxis
Interventions
Tranexamic Acid, Placebo
Drug · Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boardman, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Not applicable Interventional Results available

Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis

NCT00814333
View directory record Official record
Conditions
Epistaxis
Interventions
Thrombin-JMI, Merocel pack
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732
View directory record Official record
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT06659640
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
ALN-6400, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959
View directory record Official record
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 22, 2026, 9:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Nasal Compression Device Study for Epistaxis

NCT05789264
View directory record Official record
Conditions
Epistaxis Nosebleed
Interventions
Nasal Compression Device, Routine Care
Device · Diagnostic Test
Lead sponsor
NasaClip
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting Phase 1 Interventional

Topical TOR-582 Treatment of Epistaxis in HHT

NCT07667413
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Interventions
Topical sirolimus ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

NCT03850964
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions
Pazopanib, Placebo oral capsule
Drug
Lead sponsor
Cure HHT
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasotracheal Intubation Over a Bougie

NCT03003455
View directory record Official record
Conditions
Nasotracheal Intubation, Nasal Bleeding
Interventions
Nasotracheal intubation over a bougie, Conventional Nasotracheal Intubation
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
8 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Jul 22, 2026, 9:57 AM EDT